Cytidine deaminase (cytidine aminohydrolase, EC 3.5.4.5) was
measured in blood collected for routine antenatal monitoring from 590 unselected pregnant women. The enzyme measurements were made without prior knowledge of the clinical condition of the patients. Increased activity of cytidine deaminase was found in 42·9% of patients with severe pre-eclampsia, 9·1% of patients with mild pre-eclampsia and in 8·6% of normal pregnancies. These results show a poor correlation of elevated cytidine deaminase activity with pre-eclampsia and a significant false positive elevation of the enzyme activity in normal pregnancies.
Cytidine deaminase has been reported to be increased in the serum of pregnant women with pre-eclampsia.' The original work on deoxycytidine deaminase (deoxycytidylate aminohydrolase EC 3.5.4.12) in pregnancy/ has shown that the enzyme activity was raised in all patients with pre-eclampsia and that the enzyme activity remained constant throughout normal pregnancy. A subsequent publicatiorr' has shown patients with pre-eclampsia of undefined severity with normal deoxycytidine deaminase activity and normal patients with elevated levels of the enzyme. Work by the original authors" has reported patients with mild pre-eclampsia with normal deoxycytidine deaminase activity. Cytidine deaminase has been found to be more stable than deoxycytidine deaminase and is now the preferred enzyme for screening pregnancy sera. The correlation between the two enzyme activities is reported to be excellent. 1 The purpose of this present study was to evaluate the use of cytidine deaminase in predicting pre-eclampsia in an unselected hospital population of pregnant women.
Patients and methods
Blood was taken from 590 pregnant women for routine antenatal screening, either at a hospital clinic or on the antenatal ward. Blood was taken into lithium heparin tubes, centrifuged, separated within 2 h of collection, stored at -20°C and assayed within 5 days. Serum Correspondence: T J Baines. 420 samples were found to give identical results in the assay. Haemolysed samples were rejected. Cytidine deaminase activity was measured by the method of Jones et ae but since large numbers were to be screened, the rapid method of ammonia determination at 37°C with a glutamate dehydrogenase endpoint as described by Targett-Adams et al. 5 was employed. A normal and high activity pool, mean values 10·6 units of enzyme activity and 61·5 units of enzyme activity respectively were assayed with each batch. One unit of enzyme activity is defined as 10-" urnol of ammonia formed per min per ml at 37°C.1 The between-batch coefficient of variation for the normal and high pools was 7·2% and 7·3% respectively. The within-batch coefficient of variation for the normal pool was 5·2%.
Dilution of the highest enzyme activity found showed that the assay was linear over the range 0-59 units of enzyme activity at 37°C.
Definitions of hypertension and pre-eclampsia were taken from Williams Obstetrics" as follows:
Essential hypertension. A blood pressure of greater than 140/90 present before 20 weeks of gestation or persisting for more than 6 weeks post partum.
Mild pre-eclampsia. A blood pressure of greater than 140/90 and less than 160/110 after 20 weeks gestation or a rise in systolic blood pressure of at least 30 mmHg or in diastolic blood pressure of at least 15 mmHg, with or without proteinuria.
Severe pre-eclampsia. A systolic blood press-ure of greater than 160 mmHg or diastolic pressure of greater than 110 mmHg and/or proteinuria of greater than 5 g per 24 hours or 3-4 plus on qualitative examination.
Results
We measured the plasma activity of cytidine 60 50 deaminase in 514 patients who had a normal pregnancy with no elevation of blood pressure and a normal outcome. The cytidine deaminase reference range (mean ±2 SD) derived from the results from this population did not change significantly from 4·2-18·9 units at 28-32 weeks gestation to 4·5---18·9 units at 37 weeks to term. The overall range for all gestations was 4·3-19·1 units of enzyme activity. Figure 1 shows the details of 554 of our 590 patients. The remaining 36 patients all had pre-eclampsia of varying severity but, because of the blind nature of the study, their enzyme measurements were made from 2--6 weeks before hypertension was documented. The enzyme activities in Fig. 1 were measured at the time that the clinical conditions were present, as defined by previously stated criteria.
It can be seen that elevated cytidine deaminase activity was found in only 2 of 22 patients with mild pre-eclampsia and in 6 of 14 patients with either severe pre-eclampsia or essential hypertension with superimposed preeclampsia ( Fig. 1) .
There were 44 patients with normal pregnancies who had raised cytidine deaminase activities. None had liver disease or were carrying a multiple pregnancy. One of these patients had hereditary spherocytosis and the increased cytidine deaminase activity would be explained by the increased erythrocyte fragility in this condition." Thus there were 43 patients with an unexplained increased activity of cytidine deaminase. During the course of this study there were two unexplained intra-uterine deaths at 30 and 39 weeks gestation. Although cytidine deaminase was measured 5 and 2 days before delivery respectively, the enzyme activities were not raised.
Discussion
In the course of this study elevated cytidine deaminase activity was found in few patients with mild pre-eclampsia and in only about half of those with severe pre-eclampsia. During the study period we also saw 43 patients (giving an extrapolated rate of 76 per year) with elevated cytidine deaminase activities and normal pregnancies. These patients would pose a severe burden on the antenatal care system if it were necessary to admit them to hospital for assessment as has been advocated." The high false positive rate in normal patients and the considerable false negative rate even in the severe pre-eclampsia patients leads us to conclude that cytidine deaminase has low discriminative value for the diagnosis of pre-eclampsia and threatened intra-uterine death. Using the definitions of Yerushalmy" for assessing methods of medical diagnosis the sensitivity (true positives/total with the disease) is 22·2%, the specificity (true negatives/number without the disease) is 91·4% and the predictive accuracy of a positive result (true positives/true positives + false positives) is 15·4%.
